Service Information

Pharmaceutical and biotech companies may consider withdrawing or discontinuing more mature medicines from certain markets, potentially resulting in an unmet medical need for patients. Clinigen can provide guidance and support for developing an effective market exit strategy that ensures a coordinated approach that won’t impact patient care.

Continuation of supply through an unlicensed route, or potential acquisition of your medicine, are just some of the ways through which we can help you ensure your asset continues to be provided to the market, in a compliant, ethical manner, to the patients who need it.

How we can help Healthcare Professionals